The EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease (NAFLD) provide recommendations for the diagnosis, treatment, and follow-up of NAFLD patients. The guidelines are based on a comprehensive review of the literature up to April 2015 and are graded according to the level of evidence and strength of recommendation. NAFLD is characterized by excessive hepatic fat accumulation, associated with insulin resistance, and includes two distinct conditions: non-alcoholic fatty liver (NAFL) and non-alcoholic steatohepatitis (NASH). NASH is diagnosed through liver biopsy and is associated with fibrosis, cirrhosis, and hepatocellular carcinoma (HCC). The guidelines emphasize the importance of screening for NAFLD in high-risk populations, considering the burden on healthcare systems and the limited effectiveness of current treatments. NAFLD is prevalent in Western countries, affecting 17–46% of adults, and is closely linked to metabolic syndrome (MetS) and its components. The guidelines recommend screening for MetS in NAFLD patients, as well as for NASH and fibrosis in high-risk individuals. Non-invasive tests, such as ultrasound and serum biomarkers, are recommended for initial assessment, while liver biopsy remains the gold standard for NASH diagnosis. The guidelines also emphasize the role of lifestyle changes, including diet and exercise, in managing NAFLD, with a target of 7–10% weight loss for overweight/obese patients. Pharmacological treatments for NASH are limited, with no approved drugs available. Insulin sensitizers such as metformin and pioglitazone, as well as antioxidants like vitamin E, are discussed, though their efficacy is limited. The guidelines recommend bariatric surgery for patients unresponsive to lifestyle and pharmacological interventions, as it can significantly reduce liver fat and NASH progression. Liver transplantation is considered for end-stage liver disease, with comparable survival rates to other indications, despite higher cardiovascular mortality. The guidelines also address the management of pediatric NAFLD, emphasizing the importance of lifestyle modifications and the limited effectiveness of current treatments for fibrosis. They highlight the need for further research on non-invasive tests, drug therapies, and long-term outcomes in NAFLD patients. The guidelines aim to improve patient care, raise awareness of NAFLD, and assist stakeholders in decision-making through evidence-based recommendations.The EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease (NAFLD) provide recommendations for the diagnosis, treatment, and follow-up of NAFLD patients. The guidelines are based on a comprehensive review of the literature up to April 2015 and are graded according to the level of evidence and strength of recommendation. NAFLD is characterized by excessive hepatic fat accumulation, associated with insulin resistance, and includes two distinct conditions: non-alcoholic fatty liver (NAFL) and non-alcoholic steatohepatitis (NASH). NASH is diagnosed through liver biopsy and is associated with fibrosis, cirrhosis, and hepatocellular carcinoma (HCC). The guidelines emphasize the importance of screening for NAFLD in high-risk populations, considering the burden on healthcare systems and the limited effectiveness of current treatments. NAFLD is prevalent in Western countries, affecting 17–46% of adults, and is closely linked to metabolic syndrome (MetS) and its components. The guidelines recommend screening for MetS in NAFLD patients, as well as for NASH and fibrosis in high-risk individuals. Non-invasive tests, such as ultrasound and serum biomarkers, are recommended for initial assessment, while liver biopsy remains the gold standard for NASH diagnosis. The guidelines also emphasize the role of lifestyle changes, including diet and exercise, in managing NAFLD, with a target of 7–10% weight loss for overweight/obese patients. Pharmacological treatments for NASH are limited, with no approved drugs available. Insulin sensitizers such as metformin and pioglitazone, as well as antioxidants like vitamin E, are discussed, though their efficacy is limited. The guidelines recommend bariatric surgery for patients unresponsive to lifestyle and pharmacological interventions, as it can significantly reduce liver fat and NASH progression. Liver transplantation is considered for end-stage liver disease, with comparable survival rates to other indications, despite higher cardiovascular mortality. The guidelines also address the management of pediatric NAFLD, emphasizing the importance of lifestyle modifications and the limited effectiveness of current treatments for fibrosis. They highlight the need for further research on non-invasive tests, drug therapies, and long-term outcomes in NAFLD patients. The guidelines aim to improve patient care, raise awareness of NAFLD, and assist stakeholders in decision-making through evidence-based recommendations.